Your browser doesn't support javascript.
loading
Implementing evidence-based assertions of clinical actionability in the context of secondary findings: Updates from the ClinGen Actionability Working Group.
Pak, Christine M; Gilmore, Marian J; Bulkley, Joanna E; Chakraborty, Pranesh; Dagan-Rosenfeld, Orit; Foreman, Ann Katherine M; Gollob, Michael H; Jenkins, Charisma L; Katz, Alexander E; Lee, Kristy; Meeks, Naomi; O'Daniel, Julianne M; Posey, Jennifer E; Rego, Shannon M; Shah, Neethu; Steiner, Robert D; Stergachis, Andrew B; Subramanian, Sai Lakshmi; Trotter, Tracy; Wallace, Kathleen; Williams, Marc S; Goddard, Katrina A B; Buchanan, Adam H; Manickam, Kandamurugu; Powell, Bradford; Ezzell Hunter, Jessica.
Afiliação
  • Pak CM; Department of Translational and Applied Genomics, Kaiser Permanente Center for Health Research, Portland, OR. Electronic address: christine.pak@kpchr.org.
  • Gilmore MJ; Department of Translational and Applied Genomics, Kaiser Permanente Center for Health Research, Portland, OR.
  • Bulkley JE; Department of Translational and Applied Genomics, Kaiser Permanente Center for Health Research, Portland, OR.
  • Chakraborty P; Newborn Screening Ontario, Children's Hospital of Eastern Ontario, and Division of Metabolics University of Ottawa, Ottawa, ON, Canada.
  • Dagan-Rosenfeld O; Department of Genetics, Stanford University School of Medicine, Stanford, CA.
  • Foreman AKM; Department of Genetics, University of North Carolina, Chapel Hill, NC.
  • Gollob MH; Division of Cardiology, University of Toronto, Toronto, ON, Canada.
  • Jenkins CL; Department of Translational and Applied Genomics, Kaiser Permanente Center for Health Research, Portland, OR.
  • Katz AE; Division of Internal Medicine, University of Michigan, Ann Arbor, MI.
  • Lee K; Department of Genetics, University of North Carolina, Chapel Hill, NC.
  • Meeks N; Section of Genetics, Department of Pediatrics, University of Colorado, Aurora, CO.
  • O'Daniel JM; Department of Genetics, University of North Carolina, Chapel Hill, NC.
  • Posey JE; Molecular and Human Genetics Department, Baylor College of Medicine, Houston, TX.
  • Rego SM; Institute for Human Genetics, University of California, San Francisco, CA.
  • Shah N; Molecular and Human Genetics Department, Baylor College of Medicine, Houston, TX.
  • Steiner RD; University of Wisconsin and Marshfield Clinic, Marshfield and Madison, WI.
  • Stergachis AB; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA.
  • Subramanian SL; Molecular and Human Genetics Department, Baylor College of Medicine, Houston, TX; Roche Diagnostics, Santa Clara, CA.
  • Trotter T; Department of Pediatrics, John Muir Health, Walnut Creek, CA.
  • Wallace K; Department of Genetics, University of North Carolina, Chapel Hill, NC.
  • Williams MS; Department of Genomic Health, Geisinger, Danville, PA.
  • Goddard KAB; Department of Translational and Applied Genomics, Kaiser Permanente Center for Health Research, Portland, OR.
  • Buchanan AH; Department of Genomic Health, Geisinger, Danville, PA.
  • Manickam K; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, OH.
  • Powell B; Department of Genetics, University of North Carolina, Chapel Hill, NC.
  • Ezzell Hunter J; Genomics, Ethics, and Translational Research Program, RTI International, Research Triangle Park, NC.
Genet Med ; 26(8): 101164, 2024 May 14.
Article em En | MEDLINE | ID: mdl-38757444
ABSTRACT

PURPOSE:

The ClinGen Actionability Working Group (AWG) developed an evidence-based framework to generate actionability reports and scores of gene-condition pairs in the context of secondary findings from genome sequencing. Here we describe the expansion of the framework to include actionability assertions.

METHODS:

Initial development of the actionability rubric was based on previously scored adult gene-condition pairs and individual expert evaluation. Rubric refinement was iterative and based on evaluation, feedback, and discussion. The final rubric was pragmatically evaluated via integration into actionability assessments for 27 gene-condition pairs.

RESULTS:

The resulting rubric has a 4-point scale (limited, moderate, strong, and definitive) and uses the highest-scoring outcome-intervention pair of each gene-condition pair to generate a preliminary assertion. During AWG discussions, predefined criteria and factors guide discussion to produce a consensus assertion for a gene-condition pair, which may differ from the preliminary assertion. The AWG has retrospectively generated assertions for all previously scored gene-condition pairs and are prospectively asserting on gene-condition pairs under assessment, having completed over 170 adult and 188 pediatric gene-condition pairs.

CONCLUSION:

The AWG expanded its framework to provide actionability assertions to enhance the clinical value of their resources and increase their utility as decision aids regarding return of secondary findings.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Genet Med Assunto da revista: GENETICA MEDICA Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Genet Med Assunto da revista: GENETICA MEDICA Ano de publicação: 2024 Tipo de documento: Article